This video is featured in the 2024 ASCO® Annual Meeting Insights Hub

ecancer
X

ASCO® 2024 Summary: "IMROZ & BENEFIT Studies in Newly Diagnosed Myeloma"

By ecancer FEATURING Xavier Leleu
By ecancer FEATURING Xavier Leleu
166 views
June 24, 2024
0 Comments
Login to view comments. Click here to Login

Featured Video

16:51
Incyte

Effects of PV Treatment on White Blood Cell Count and Thrombotic Risk

Feat. C. Harrison

Featured Video

16:26
Incyte

Effects of a Treatment Option on Hematocrit Control and Spleen Volum…

Feat. C. Harrison

2024 ASCO® Annual Meeting Insights Hub: Hematologic Oncology Videos

06:26
ecancer

Post-Transplant Cyclophosphamide Based GVHD Prophylaxis in Patients …

Feat. M. Al Malki, S. Devine
09:04
ecancer

ASCO® 2024 Insights: "Importance of MRD in Newly Diagnosed Mult…

Feat. X. Leleu
27:49
Insights from 2024 EHA Annual Meeting

AML, MDS, and CML Highlights & Key Takeaways From ASCO®/EHA 2024

Feat. T. Badar
View All

Related Content

AUTOPLAY
21:05
Louisville Hematology Highlights

Why Are Our Hematopoietic Stem Cells in the Bone Marrow?

Feat. R. Gale
17:52
Indy Hematology Review

2024 Updates on Emerging & Current Treatment of Multiple Myeloma

Feat. K. Anderson
16:42
Insights from 2023 ASH Annual Meeting

ASH 2023 Summary: "The Best of Myeloma - Highlights & Key T…

Feat. H. Hashmi
24:35
2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Summary: "The Best of Myeloma - Review of the Top 5 …

Feat. H. Hashmi
17:46
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Highlights in 1L MM - Quadruplet Therapies …

Feat. A. Jakubowiak
09:51
i3 Health

MRD Testing in Leukemias: When Negativity Is a Positive Thing

Feat. N. S. Raje
24:23
MyCancerHaven

Will CAR-Ts and Bispecifics Will Replace HSCT in Myeloma?

Feat. R. Vij, S. Al Hadidi
24:44
Indy Hematology Review

State of the Art in 2024: Emerging Therapies in Hematologic Malignan…

Feat. R. Birhiray
13:15
2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Summary: "Quadruplets in NDMM - The More the Better?…

Feat. O. Landgren
36:10
Insights from 2024 EHA Annual Meeting

Highlights in Plasma Cell Disorders From ASCO® and EHA

Feat. S. Al Hadidi
28:20
Indy Hematology Review

Managing Newly Diagnosed MM in 2024

Feat. S. Usmani
35:27
Dana-Farber Cancer Institute

Advances in Multiple Myeloma 2024: From Bench to Bedside

Feat. K. Anderson
19:24
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Updates on Managing Newly Diagnosed MM - In…

Feat. P. Richardson
13:47
2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Insights: "MRD2STOP Study - Discontinuation of Maint…

Feat. B. Derman
20:23
SOHO Brazil 2024

When to Consider Bispecific and CAR-T Therapy in MM

Feat. N. S. Raje
06:19
Insights from 2023 ASH Annual Meeting

Dara-KRd in NDMM Without ASCT: Final Analysis of a Ph2 Trial

Feat. B. Derman
22:33
Integrity CE

Treatment Strategies for R/R MM After Frontline Anti-CD38 Therapy

Feat. S. Usmani, J. Hillengass
20:19
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "Highlights of Hematologic Malignancies - …

Feat. A. Paulus
35:37
University of Colorado Division of Hematology

2024 Updates on Multiple Myeloma Treatment

Feat. D. Sherbenou
19:20
2024 ASCO® Annual Meeting Insights Hub

Highlights of Recent Updates in Myeloma: Part 1 - Frontline Treatment

Feat. A. Jakubowiak